VSIR and cancer: Given the positive outcomes of targeting VISTA in pre-clinical trials (182), and considering that PSGL-1 has been established as a binding partner for VISTA and as an immune checkpoint molecule, PSGL-1 should be considered as a potential therapeutic target for cancer in human clinical trials.